You are here

P&T July 2014

Features

Pharmacies Will Have Options ... and Costs
The FDA is trying to decide how to implement a new law by January 1, 2015, that requires manufacturers, wholesalers, and pharmacies to trace drug products as they move through the distribution chain. A degree of turmoil appears likely to result.
Health care professionals can use a variety of social media tools to improve or enhance networking, education, and other activities. However, these tools also present some potential risks, such as unreliable information and violations of patients’ privacy rights.
Defects in a single gene lead to the defective proteins that cause cystic fibrosis, making the disease an ideal candidate for mutation-targeted therapy. Although ivacaftor is currently the only FDA-approved CFTR modifier, others are in development.
Pipeline Plus
As better drugs from a variety of pharmaceutical industry players enter a market with millions of untreated patients, U.S. spending on hepatitis C treatments is expected to rise from $2.1 billion in 2012 to $6.5 billion in 2022.

Departments

Medication Errors
Take steps to prevent ingestion or aspiration of objects
Prescription: Washington
Medicare ditches medication therapy management changes

FDA approvals, drug indications, and updates

Albiglutide (Tanzeum) for type-2 diabetes, ramucirumab (Cyramza) for advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma, and ceritinib (Zykadia) for metastatic non–small-cell lung cancer

Drug Forecast
Ibrutinib (Imbruvica): a novel targeted therapy for chronic lymphocytic leukemia
Meeting Highlights

The American Society of Clinical Oncology meeting drew more than 34,600 people to Chicago to learn about the latest research, including studies on lymphoma, pancreatic cancer, colon cancer, melanoma, multiple myeloma, and palliative care.